Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juan, C. Articles by Oliver, A. Search for Related Content PubMed PubMed Citation Articles by Juan, C. Articles by Oliver, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2006, p. 1780-1787, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1780-1787.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level ß-Lactam Resistance Involves Three AmpD Homologues

Carlos Juan, Bartolomé Moyá, José L. Pérez, and Antonio Oliver^*

Servicio de Microbiología, Hospital Son Dureta, Palma de Mallorca, Spain

Received 7 January 2006/ Returned for modification 13 February 2006/ Accepted 6 March 2006

Top Abstract Introduction Materials and Methods Results Discussion References

 
Development of resistance to the antipseudomonal penicillins and cephalosporins mediated by hyperproduction of the chromosomal cephalosporinase AmpC is a major threat to the successful treatment of Pseudomonas aeruginosa infections. Although ampD inactivation has been previously found to lead to a partially derepressed phenotype characterized by increased AmpC production but retaining further inducibility, the regulation of ampC in P. aeruginosa is far from well understood. We demonstrate that ampC expression is coordinately repressed by three AmpD homologues, including the previously described protein AmpD plus two additional proteins, designated AmpDh2 and AmpDh3. The three AmpD homologues are responsible for a stepwise ampC upregulation mechanism ultimately leading to constitutive hyperexpression of the chromosomal cephalosporinase and high-level antipseudomonal ß-lactam resistance, as shown by analysis of the three single ampD mutants, the three double ampD mutants, and the triple ampD mutant. This is achieved by a three-step escalating mechanism rendering four relevant expression states: basal-level inducible expression (wild type), moderate-level hyperinducible expression with increased antipseudomonal ß-lactam resistance (ampD mutant), high-level hyperinducible expression with high-level ß-lactam resistance (ampD ampDh3 double mutant), and very high-level (more than 1,000-fold compared to the wild type) derepressed expression (triple mutant). Although one-step inducible-derepressed expression models are frequent in natural resistance mechanisms, this is the first characterized example in which expression of a resistance gene can be sequentially amplified through multiple steps of derepression.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Pseudomonas aeruginosa is a ubiquitous versatile environmental microorganism that is the leading cause of opportunistic human infections (40). This pathogen is frequently involved in acute nosocomial infections, especially affecting patients in intensive care units (ICUs) with mechanical-ventilation-associated pneumonia or burn wound infections, both processes associated with a high mortality rate (41). P. aeruginosa is also the major cause of chronic respiratory infections in patients with cystic fibrosis and other underlying chronic respiratory diseases (12).

P. aeruginosa resistance development during antimicrobial therapy, mediated by the selection of mutations in certain chromosomal genes, is a frequent problem with major clinical consequences, especially when affecting critical patients in ICUs or in chronically colonized patients, where this problem is amplified because of the high prevalence of hypermutable strains (5, 7, 17, 29, 35). The most relevant mechanism for development of resistance to antipseudomonal penicillins (such as ticarcillin or piperacillin) and cephalosporins (such as ceftazidime or cefepime) is selection of mutations leading to hyperproduction of the chromosomal cephalosporinase AmpC (11, 26). AmpC is a group I class C ß-lactamase present in most Enterobacteriaceae and in P. aeruginosa and other nonfermenting gram-negative bacilli (4, 27). With the exception of Escherichia coli and shigellae, ß-lactamase is produced at low basal levels but its expression is inducible by certain ß-lactams, especially cefoxitin and imipenem. The activity of the antipseudomonal penicillins and cephalosporins against P. aeruginosa is based on the fact that although these compounds are certainly hydrolyzed by AmpC, they are very weak inducers of this chromosomal ß-lactamase (27, 28). Nevertheless, during treatment with ß-lactams, resistant mutants showing high levels of AmpC production are frequently selected, leading to therapeutic failure (11, 17).

There are several genes involved in ampC induction, a process that is intimately linked to peptidoglycan recycling (32). This system was first characterized in Enterobacteriaceae (Enterobacter cloacae and Citrobacter freundii) and later found to be conserved also in P. aeruginosa (22, 30). Of the genes involved, ampR, which is contiguous to ampC but divergently transcribed, encodes a transcriptional regulator of the LysR family that is required for ß-lactamase induction (14, 24); ampG encodes a transmembrane protein that functions as a permease for 1,6-anhydromurapeptides, which are thought to be the signal molecules involved in ampC induction (6, 21); ampD, which encodes a cytosolic N-acetyl-anhydromuramyl-L-alanine amidase that hydrolyzes 1,6-anhydromurapeptides, acting as a repressor of ampC expression (13, 25); and ampE, which forms the bicistronic ampDE operon together with ampD, encodes a cytoplasmic membrane protein thought to act as a sensory transducer molecule required for induction (15).

Mutational inactivation of ampD is the main mechanism found to lead to the constitutive hyperproduction (derepression) of AmpC, and consequently to ß-lactam resistance, in Enterobacteriaceae (25, 39). The accumulated 1,6-anhydromurapeptides produced by ampD inactivation presumably bind to AmpR, converting it into an activator of ampC expression (16).

Although the regulation of ampC in P. aeruginosa is not well understood, ampD inactivation has been previously found to lead to a partially derepressed phenotype characterized by increased AmpC production but retaining further inducibility (23). We demonstrate that ampC expression is coordinately repressed by three ampD homologues, the previously described ampD gene (22) plus two additional homologous genes, PA5485 and PA0807, from the completely sequenced PAO1 strain (40), here designated ampDh2 and ampDh3, respectively. These three AmpD homologues are responsible for a stepwise ampC upregulation mechanism ultimately leading to the constitutive hyperexpression (more than 1,000-fold) of the chromosomal cephalosporinase and high-level (clinically relevant) antipseudomonal ß-lactam resistance.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Bacterial strains, plasmids, and antibiotic susceptibility testing. The wild-type Pseudomonas aeruginosa strain used in this work was the completely sequenced reference strain PAO1 (40). The PAO1 mutant derivatives constructed, the plasmids used or constructed, and the E. coli strains used in this work are described in Table 1. The MICs of the antipseudomonal ß-lactams ceftazidime, cefepime, ticarcillin, piperacillin, piperacillin-tazobactam, aztreonam, imipenem, and meropenem were determined in Müller-Hinton agar plates with Etest strips (AB Biodisk, Solna, Sweden) by following the manufacturer's recommendations.

View this table: [in this window] [in a new window]

TABLE 1. Strains and plasmids used in this study

Cloning of ampD homologues ampDh2 and ampDh3. The P. aeruginosa ampD homologues ampDh2 (PA5485) and ampDh3 (PA0807) were detected by homology searches with the BLAST program at www.ncbi.nlm.nih.gov/BLAST. For cloning of ampDh2 and ampDh3, the PAO1 wild-type genes were PCR amplified with the primers described in Table 2. PCR products were ligated to plasmid pGEM-T to obtain pGTADh2 or pGTADh3, respectively, which were transformed into E. coli XL1-Blue made competent by CaCl₂. Transformants were selected in 50 µg/ml ampicillin MacConkey agar plates. The ampDh2 and ampDh3 genes obtained from three independent experiments were fully sequenced to ascertain the absence of mutations in the cloned fragments produced during PCR amplification. The BigDye Terminator Kit (PE-Applied Biosystems) was used to perform the sequencing reactions, which were analyzed with an ABI Prism 3100 DNA sequencer (PE-Applied Biosystems). Plasmid DNAs from pGTADh2 and pGTADh3 digested with BamHI were ligated to plasmid pUCP24 digested with the same enzyme to obtain plasmids pUCPADh2 and pUCPADh3, which were transformed into E. coli XL1-Blue. Transformants were selected in 20 µg/ml gentamicin MacConkey agar plates. In both cases, recombinant plasmids with DNA inserts with an orientation opposite to that of the lacZ promoter were selected.

View this table: [in this window] [in a new window]

TABLE 2. Primers used in this work

Inactivation of P. aeruginosa ampD homologues. PAO1 ampD (PAD), ampDh2 (PADh2), and ampDh3 (PADh3) knockout mutants, as well as the three double mutants (ampD ampDh2 [PADDh2], ampD ampDh3 [PADDh3], and ampD2 ampDh3 [PADh2Dh3]) and the triple mutant (ampD ampDh2 ampDh3 [PADDh2Dh3]), were constructed by following the procedure previously described by Quénée et al. (36) for gene deletion and antibiotic marker recycling in P. aeruginosa. Upstream and downstream PCR products (Table 2) of ampD, ampDh2, or ampDh3 were digested with either BamHI or EcoRI and HindIII and cloned by three-way ligation into pEX100Tlink with the HindIII site deleted and opened by EcoRI and BamHI to obtain plasmids pEXTAD, pEXTADh2, and pEXTADh3, which were transformed into E. coli XL1-Blue. Transformants were selected in 50 µg/ml ampicillin MacConkey agar plates. The lox-flanked gentamicin resistance cassette (aacC1) obtained by HindIII restriction of plasmid pUCGmlox was cloned into the single site for this enzyme formed by ligation of the two flanking fragments, producing plasmids pEXTADGm, pEXTADh2Gm, and pEXTADh3Gm, which were transformed into E. coli XL1- Blue. Transformants were selected in 50 µg/ml ampicillin-20 µg/ml gentamicin MacConkey agar plates. These plasmids were then transformed into E. coli helper strain S17-1. The PAD, PADh2, and PADh3 PAO1 mutants were generated by, respectively, introducing pEXTADGm, pEXTADh2Gm, and pEXTADh3Gm from E. coli S17-1 by conjugation and selection for double recombinants with 5% sucrose-30 µg/ml gentamicin-1 µg/ml cefotaxime Luria-Bertani (LB) agar plates. Double recombinants were checked first by screening for ticarcillin (250 µg/ml) susceptibility and afterwards by PCR amplification. For removal of the gentamicin resistance cassettes, plasmid pCM157 was electroporated into the different mutants as previously described (38). Transformants were selected in 250 µg/ml tetracycline LB agar plates. One transformant for each mutant was grown overnight in 250 µg/ml tetracycline LB broth in order to allow expression of the cre recombinase. Plasmid pCM157 was then cured from the strains by three successive passages on LB broth. Selected colonies were then screened for tetracycline and gentamicin susceptibility. Finally, the knockout mutants were checked by PCR amplification and sequencing to ascertain that the corresponding genes were properly disrupted. The three double mutants and the triple mutant were then constructed from the single mutants sequentially by the same procedure.

Quantification of ß-lactamase activity. ß-Lactamase specific activity (nanomoles of nitrocefin hydrolyzed per minute per milligram of protein) was determined spectrophotometrically on crude sonic extracts from strain PAO1 and the seven above-described ampD mutants as previously described (18). To determine the ß-lactamase specific activity after induction, before the preparation of the crude sonic extracts, the strains were grown in the presence of 50 µg/ml cefoxitin for 3 h. Alternatively, when specifically indicated, induction experiments were performed by incubation in the presence of ceftazidime (0.5 or 20 µg/ml). In all cases, the mean ß-lactamase activity values obtained in three independent experiments were considered. The phenotypic determination of AmpC inducibility was performed by assessing the presence of antagonism between imipenem and ceftazidime disks in Müller-Hinton agar plates.

Quantification of the expression of ampC, ampD, ampE, ampDh2, and ampDh3. The levels of expression of ampC, ampD, ampE, ampDh2, and ampDh3 were determined by real-time PCR in strain PAO1 and the seven ampD mutants with and without cefoxitin induction. Total RNA from logarithmic-phase-grown cultures (with and without 50 µg/ml cefoxitin) was obtained with the RNeasy Mini Kit (QIAGEN, Hilden, Germany) and adjusted to a final concentration of 50 ng/µl. A 500-ng sample of purified RNA was then used for one-step reverse transcription and real-time PCR amplification with the QuantiTect SYBR Green RT-PCR Kit (QIAGEN, Hilden, Germany) in a SmartCycler II (Cepheid, Sunnyvale, CA). The primers listed in Table 2 and previously described RpsL-1 and RpsL-2 (34) were used for amplification of ampC, ampD, ampE, ampDh2, ampDh3, and rpsL (used as a reference to calculate the relative amount of mRNA). In all cases, the mean values of relative mRNA expression obtained in three independent duplicate experiments were considered.

Complementation assays. For complementation experiments, plasmids pUCPADh2 and pUCPADh3; previously described plasmids pUCPAD and pUCPADE, harboring the PAO1 wild-type ampD gene and the complete ampDE operon, respectively (18); and plasmid pUCP24 (as a control) were electroporated into the different ampD mutants or PAO1. Transformants were selected in 50 µg/ml gentamicin LB agar plates. Ceftazidime MICs and ß-lactamase activity were determined to evaluate the complementation of the AmpC hyperproduction phenotypes.

Top Abstract Introduction Materials and Methods Results Discussion References

 
ampDh2 and ampDh3 are functional ampD homologues. Figure 1 shows a ClustalW multiple-sequence alignment of the predicted amino acid sequences of AmpDh2 and AmpDh3 compared to the AmpD proteins from P. aeruginosa and several Enterobacteriaceae. AmpDh2 and AmpDh3 were 27 and 25% identical to P. aeruginosa AmpD and 26 and 26% identical to E. cloacae AmpD, respectively. The percentage of identity between AmpDh2 and AmpDh3 was 40%. PCR and sequencing of ampDh2 and ampDh3 from 10 different clonal types of P. aeruginosa clinical strains confirmed that both genes are highly conserved in this species. Furthermore, both AmpDh2 and AmpDh3 contain all of the residues previously found to be essential for C. freundii AmpD catalytic activity, including His34, His154, Lys162, and Asp164 (9). ampDh2 is located in the chromosome of PAO1, between the alginate production regulatory gene kinB (PA5484) and PA5486, coding for a protein of unknown function, whereas ampDh3 is located between PA0806 and PA0808, both encoding theoretical proteins of unknown function.

View larger version (42K): [in this window] [in a new window]

FIG. 1. ClustalW multiple-sequence alignment of P. aeruginosa AmpDh2 and AmpDh3 and the previously described AmpD proteins from P. aeruginosa, E. coli, E. cloacae, and C. freundii. Conserved residues previously found to be essential for C. freundii AmpD catalytic activity (9) are in bold. Dashes indicate gaps. Asterisks, colons, and periods indicate identical, conserved, and semiconserved residues, respectively.

As previously noted (23), inactivation of ampD in strain PAO1 (PAD) led to a partially derepressed phenotype characterized by increased AmpC production but retaining further inducibility. This phenotype was associated with an eightfold increase in the ceftazidime MICs. As shown in Table 3, the plasmids harboring ampDh2 (pUCPADh2) and ampDh3 (pUCPADh3) completely transcomplemented the AmpC hyperproduction phenotype of PAD as readily as those harboring the regular ampD gene (pUCPAD) and the complete ampDE operon (pUCPADE), demonstrating that they both have functional N-acetyl-anhydromuramyl-L-alanine amidase activity.

View this table: [in this window] [in a new window]

TABLE 3. Complementation of the AmpC hyperproduction phenotype of the PAO1 ampD mutant (PAD) with plasmids harboring wild-type ampD (pUCPAD), ampDE (pUCPADE), ampDh2 (pUCPADh2), and ampDh3 (pUCPADh3)

Role of ampD homologues in ampC regulation and ß-lactam resistance. Table 4 shows the levels of ampC expression under basal and cefoxitin-induced conditions and the susceptibilities to the antipseudomonal ß-lactams of strains PAO1 and the seven ampD single, double, and triple mutants. ampD inactivation in strain PAO1 (PAD) led to a 60-fold increase in ampC expression, reaching 150-fold under cefoxitin induction, and was associated with a significant increase, albeit not surpassing CLSI nonsusceptibility breakpoints, of the MICs of all of the antipseudomonal penicillins and cephalosporins. The resistance increase was highest for piperacillin, piperacillin-tazobactam, and ceftazidime and lowest for ticarcillin and cefepime. As for the highly ß-lactamase hydrolysis-resistant carbapenems, the MICs of imipenem were not significantly affected but those of meropenem were considerably raised, albeit they remained far from the nonsusceptibility breakpoints. On the other hand, the inactivation of neither ampDh2 nor ampDh3 (PADh2 and PADh3) significantly modified ampC expression or the antipseudomonal ß-lactam MICs. Furthermore, the ampDh2-ampDh3 double inactivation (PADh2Dh3) only slightly increased ampC basal and induced expression (twofold compared to PAO1) but did not produce any increase in ß-lactam resistance, rather the opposite; MICs were 1 dilution lower than those of some of the antibiotics for PAO1 (Table 4).

View this table: [in this window] [in a new window]

TABLE 4. Levels of ampC expression under basal and cefoxitin-induced conditions and MICs of antipseudomonal ß-lactams for strain PAO1 and seven ampD mutants

This apparent lack of effect of the ampD homologues on the regulation of the chromosomal cephalosporinase and ß-lactam resistance drastically changed when the ampD ampDh2 (PADDh2) and ampD ampDh3 (PADDh3) double mutants were analyzed. Regarding ampC expression, PADDh2 caused only a modest increase in the inducibility of ß-lactamase compared to PAD, whereas PADDh3 caused a dramatic increase in both the basal and induced ampC levels (Table 4). The effect of PADDh2 on ß-lactam resistance was variable; it greatly increased the cefepime, aztreonam, and ticarcillin MICs, modestly increased those of ceftazidime, and modestly reduced those of piperacillin (with and without tazobactam) and meropenem compared to PAD. On the other hand, PADDh3 dramatically increased the MICs (surpassing the clinical resistance breakpoints) of all of the antipseudomonal penicillins and cephalosporins and further increased the MICs of the carbapenem ß-lactam meropenem. Finally, the triple mutant PADDh2Dh3 caused a dramatic increase in the basal ampC expression level (1,000-fold compared to PAO1, 17-fold compared to PAD), which was not further cefoxitin inducible, showing that, finally, complete derepression was reached. Initially surprising, the antipseudomonal ß-lactam MICs were not significantly raised for the completely derepressed triple mutant compared to the double mutant PADDh3. The explanation for this apparently odd finding was found to be actually simple: subinhibitory concentrations of the, in theory, weak AmpC inducer ß-lactams such as ceftazidime induced PADDh3 AmpC production to values 1,000-fold higher than that of PAO1 (reaching the level of complete derepression) just as well as the potent inducer cefoxitin, as shown in Table 5.

View this table: [in this window] [in a new window]

TABLE 5. Basal and cefoxitin- and ceftazidime-induced ß-lactamase activities of double mutant PADDh3 and triple mutant PADDh2Dh3

Model for stepwise upregulation of ampC and high-level ß-lactam resistance. From the above-described results, it can be deduced that upregulation to full derepression of the expression of P. aeruginosa ampC is achieved by a three-step escalating mechanism rendering four relevant expression states (shown in Fig. 2) and resistance phenotypes (pictures shown in Fig. 3): basal-level inducible expression (PAO1 wild type), moderate-level hyperinducible expression with increased antipseudomonal ß-lactam resistance (PAD), high-level hyperinducible expression with high-level ß-lactam resistance (PADDh3), and very high-level derepressed expression not further increasing the already high-level ß-lactam resistance (PADDh2Dh3).

View larger version (8K): [in this window] [in a new window]

FIG. 2. Representation of the three-step escalating mechanism rendering four relevant expression states: basal-level inducible expression (PAO1), moderate-level hyperinducible expression (PAD), high-level hyperinducible expression (PADDh3), and very high-level derepressed expression (PADDh2Dh3).

View larger version (61K): [in this window] [in a new window]

FIG. 3. Assessment of AmpC inducibility and antipseudomonal ß-lactam resistance phenotypes with imipenem (IPM) and ceftazidime (CAZ) disks. PAO1, highly ceftazidime susceptible, AmpC-inducible phenotype; PAD, moderately ceftazidime resistant, AmpC-inducible phenotype; PADDh3, highly ceftazidime resistant, apparently derepressed phenotype (produced by ceftazidime induction of AmpC to the maximum production level); PADDh2Dh3, highly ceftazidime resistant, AmpC-derepressed phenotype.

Interestingly, as shown in Table 6, any of the three ampD homologues, when produced from the high-copy-number pUCP24 derivatives (pUCPAD, pUCPADh2, and pUCPADh3), returned the very high-level derepressed expression and high-level ß-lactam resistance of PADDh2Dh3 to wild-type PAO1 levels, showing that the multiple-step upregulation model responds to quantitative rather than qualitative differences among the three ampD homologues involved.

View this table: [in this window] [in a new window]

TABLE 6. Complementation of the AmpC hyperproduction phenotype of the PAO1 ampD triple mutant (PADDh2Dh3) with plasmids harboring wild-type ampD (pUCPAD), ampDE (pUCPADE), ampDh2 (pUCPADh2), and ampDh3 (pUCPADh3)

Expression of ampD homologues is not regulated by AmpC inducers. The levels of expression of ampD, ampE, ampDh2, and ampDh3 genes from strain PAO1 were quantified under basal and cefoxitin-induced conditions to find out if the expression of any of them was modified (up- or downregulated) by incubation in the presence of AmpC inducers, but no significant differences in the levels of mRNA were detected (data not shown). Similarly, the inactivation of any of the ampD homologues did not modify the expression of the other ampD genes (i.e., the expression of ampDh2 or ampDh3 was not modified in PAD compared to PAO1, and the same for the other combinations), showing that the expression of the different ampD homologues apparently is not interregulated. Finally, ampD inactivation did not cause an increase in its own transcription, which would be consistent with the constitutive expression of this gene. In contrast, the transcription of ampDh2 or ampDh3 was slightly increased when the respective gene was inactivated: a two- to fivefold increase in ampDh2 or ampDh3 mRNA was observed for all of the single, double, and triple ampDh2 (PADh2, PADDh2, PADh2Dh3, and PADDh2Dh3)- or ampDh3 (PADh3, PADDh3, PADh2Dh3, and PADDh2Dh3)-inactivated mutants, respectively, compared to wild-type PAO1. These results suggest that the expression of ampDh2 and ampDh3 is inducible.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Development of resistance to the antipseudomonal penicillins and cephalosporins mediated by hyperproduction of the chromosomal cephalosporinase AmpC is a major threat to the successful treatment of P. aeruginosa infections, especially those affecting critical patients in ICUs or in chronically colonized patients such as those suffering from cystic fibrosis. Although ampD inactivation has been previously found to lead to a partially derepressed phenotype (23) and a few natural ampD mutants have been characterized (1, 18), the regulation of ampC in P. aeruginosa is far from well understood. In this work, we show that the regulation of the P. aeruginosa cephalosporinase is likely the most sophisticated repression-derepression system described in the microbial world so far, finding that ampC expression is coordinately repressed by three ampD homologues. These three AmpD homologues are responsible for a stepwise ampC upregulation mechanism ultimately leading to constitutive hyperexpression (more than 1,000-fold) of the chromosomal cephalosporinase and high-level (clinically relevant) antipseudomonal ß-lactam resistance. Although one-step inducible-derepressed expression models are frequent in natural resistance mechanisms, this is the first characterized example in which expression can be sequentially amplified through multiple steps of derepression.

Development of resistance by AmpC hyperproduction is also a major resistance threat in Enterobacteriaceae such as E. cloacae and C. freundii, where the role of AmpD as a repressor of ß-lactamase expression was actually first characterized (13, 25). In principle, it is generally accepted that in Enterobacteriaceae, AmpC is regulated by a one-step inducible-derepressed expression model in which constitutive hyperproduction is reached by AmpD inactivation. Nevertheless, homology searches of the databases with the complete sequences of E. coli and other members of the family Enterobacteriaceae revealed the presence of one, and just one, ampD homologue in addition to the regular ampD gene. In the light of this finding, it is tempting to speculate that ampC regulation in Enterobacteriaceae actually may respond to a two-step inducible-derepressed expression model. Previous findings showing a semiconstitutive AmpC hyperproduction phenotype in C. freundii ampD mutants may support this hypothesis (25).

Further studies are necessary to elucidate the in vivo dynamics of the AmpC derepression mediated by the three AmpD homologues during the treatment of P. aeruginosa infections with ß-lactams and the interplay between the three described ampC repressors and other physiological functions, since the regulation of the chromosomal ß-lactamases is intimately linked to cell wall recycling, which may modulate bacterial virulence (8, 22). The presence of up to three AmpD homologues in P. aeruginosa may certainly be beneficial for this microorganism because in addition to allowing it to acquire different levels of ß-lactamase expression and ß-lactam resistance, it may, in the ampD single mutant or in the ampD ampDh2 or ampD ampDh3 double mutant (partially derepressed phenotypes), permit hyperproduction of the cephalosporinase without disrupting the cell wall recycling process.

Interestingly, one of the ampD homologues (ampDh2) is located just contiguous to the alginate production regulatory genes algB and kinB (40). The reciprocal interaction between the ampC regulatory machinery and other cellular processes is indeed an issue of high potential relevance. For instance, Nuñez et al. (33) found that the ampDE operon of Azotobacter vinelandii is involved in alginate production and bacterial encystment. In this sense, Bagge et al. (2) found that the most potent AmpC inducer, imipenem, increased not only the expression of the chromosomal ß-lactamase but also that of the genes coding for alginate biosynthesis in P. aeruginosa biofilms. It is noteworthy that alginate hyperproduction is a key factor in the development of P. aeruginosa chronic infections such as those of cystic fibrosis patients (12). Finally, it remains to be elucidated whether, in addition to their role as ampC repressors, the three AmpD homologues affect the expression of the gene encoding the recently described P. aeruginosa oxacillinase OXA-50 or PoxB (10, 19). This ß-lactamase has been recently shown to be negatively regulated by AmpR, which is the opposite of the observed effect on ampC expression (20).

In summary, we describe the highly sophisticated mechanism of stepwise upregulation of the P. aeruginosa chromosomal cephalosporinase ultimately leading to constitutive hyperexpression of AmpC and high-level antipseudomonal ß-lactam resistance. This system is the first characterized example in which the expression of a resistance mechanism can be sequentially amplified through multiple steps of derepression.

 
We are grateful to Benoit Polack for the gift of plasmids pEX100Tlink, pUCGmlox, and pCM157.

This work was supported by grants from the Ministerio de Educación y Ciencia and the Red Española de Investigación en Patología Infecciosa (REIPI), C03-014, from the Ministerio de Sanidad of Spain.

 
* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Son Dureta, C. Andrea Doria No. 55, 07014 Palma de Mallorca, Spain. Phone: 34 971 175 185. Fax: 34 971 175 185. E-mail: aoliver{at}hsd.es.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Bagge, N., O. Ciofu, M. Hentzer, J. I. A. Campbell, M. Givskov, and N. Hoiby. 2002. Constitutive high expression of chromosomal ß-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46:3406-3411.[Abstract/Free Full Text]
2
2. Bagge, N., M. Schuster, M. Morten, O. Ciofu, M. Givskov, E. P. Greenberg, and N. Hoiby. 2004. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and ß-lactamase and alginate production. Antimicrob. Agents Chemother. 48:1175-1187.[Abstract/Free Full Text]
3
3. Bullock, W. O., J. M. Fernandez, and J. M. Short. 1987. XL1 Blue: a high efficiency plasmid transforming recA Escherichia coli strain with ß-galactosidase selection. BioTechniques 5:376-378.
4
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for ß-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.[Medline]
5
5. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. S. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risk associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.[Abstract/Free Full Text]
5
6. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
6
7. Dietz, H., D. Pfeifle, and B. Wiedemann. 1997. The signal molecule for ß-lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide. Antimicrob. Agents Chemother. 41:2113-2120.[Abstract]
7
8. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.[Medline]
8
9. Folkesson, F., S. Eriksson, M. Andersson, J. T. Park, and S. Normark. 2005. Components of the peptidoglycan-recycling pathway modulate invasion and intracellular survival of Salmonella enterica serovar Typhimurium. Cell. Microbiol. 7:147-155.[CrossRef][Medline]
9
10. Généreux, C., D. Dehareng, B. Devreese, J. van Beeumen, J. M. Frère, and B. Joris. 2004. Mutational analysis of the catalytic centre of the Citrobacter freundii AmpD N-acetylmuramyl-L-alanine amidase. Biochem. J. 377:111-120.[CrossRef][Medline]
10
11. Girlich, D., T. Naas, and P. Nordmann. 2004. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48:2043-2048.[Abstract/Free Full Text]
11
12. Giwercman, B., P. A. Lambert, V. T. Rosdahl, G. H. Shand, and N. Hoiby. 1990. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed ß-lactamase producing strains. J. Antimicrob. Chemother. 26:247-259.[Abstract/Free Full Text]
12
13. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.[Abstract/Free Full Text]
13
14. Höltje, J. V., U. Kopp, A. Ursinus, and B. Wiedemann. 1994. The negative regulator of ß-lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase. FEMS Microbiol. Lett. 122:159-164.[CrossRef][Medline]
14
15. Honore, N., M. H. Nicolas, and S. T. Cole. 1986. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO J. 5:3709-3714.[Medline]
15
16. Honore, N., M. H. Nicolas, and S. T. Cole. 1989. Regulation of enterobacterial cephalosporinase production: the role of a membrane-bound sensory transducer. Mol. Microbiol. 3:1121-1130.[CrossRef][Medline]
16
17. Jacobs, C., L. Huang, E. Bartowsky, S. Normark, and J. T. Park. 1994. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for ß-lactamase induction. EMBO J. 13:4684-4694.[Medline]
17
18. Juan, C., O. Gutiérrez, A. Oliver, J. I. Ayestarán, N. Borrell, and J. L. Pérez. 2005. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infect. 11:887-892.[CrossRef][Medline]
18
19. Juan, C., M. D. Maciá, O. Gutiérrez, C. Vidal, J. L. Pérez, and A. Oliver. 2005. Molecular mechanisms of ß-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738.[Abstract/Free Full Text]
19
20. Kong, K. F., S. R. Jayawardena, A. del Puerto, L. Wichlmann, U. Laabs, B. Tummler, and K. Mathee. 2005. Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. Gene 358:82-92.[CrossRef][Medline]
20
21. Kong, K. F., S. R. Jayawardena, S. D. Indulkar, A. del Puerto, C. L. Koh, N. Hoiby, and K. Mathee. 2005. Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB ß-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob. Agents Chemother. 49:4567-4575.[Abstract/Free Full Text]
21
22. Korfmann, G., and C. C. Sanders. 1989. ampG is essential for high-level expression of AmpC ß-lactamase in Enterobacter cloacae. Antimicrob. Agents Chemother. 33:1946-1951.[Abstract/Free Full Text]
22
23. Langaee, T. Y., M. Dargis, and A. Huletsky. 1998. An ampD gene of Pseudomonas aeruginosa encodes a negative regulator of AmpC ß-lactamase expression. Antimicrob. Agents Chemother. 42:3296-3300.[Abstract/Free Full Text]
23
24. Langaee, T. Y., L. Gagnon, and A. Huletsky. 2000. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC ß-lactamase expression. Antimicrob. Agents Chemother. 44:583-589.[Abstract/Free Full Text]
24
25. Lindberg, F., L. Westman, and S. Normark. 1985. Regulatory components in Citrobacter freundii ampC ß-lactamase induction. Proc. Natl. Acad. Sci. USA 82:4620-4624.[Abstract/Free Full Text]
25
26. Lindberg, F., S. Lindquist, and S. Normark. 1987. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii ß-lactamase. J. Bacteriol. 169:1923-1928.[Abstract/Free Full Text]
26
27. Livermore, D. M. 1987. Clinical significance of ß-lactamase induction and stable derepression in gram-negative rods. Eur. J. Clin. Microbiol. 6:439-445.[CrossRef][Medline]
27
28. Livermore, D. M. 1995. ß-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.[Abstract]
28
29. Livermore, D. M., and D. F. J. Brown. 2001. Detection of ß-lactamase-mediated resistance. J. Antimicrob. Chemother. 48:59-64.[Abstract]
29
30. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.[CrossRef][Medline]
30
31. Lodge, J., S. Busby, and L. Piddock. 1993. Investigation of the Pseudomonas aeruginosa ampR gene and its role at the chromosomal ampC promoter. FEMS Microbiol. Lett. 111:315-320.[Medline]
31
32. Marx, C. J., and M. E. Lidstrom. 2002. Broad-host-range cre-lox system for antibiotic marker recycling in gram-negative bacteria. BioTechniques 33:1062-1067.[Medline]
32
33. Normark, S. 1995. ß-Lactamase induction in gram-negative bacteria is intimately linked to peptidoglycan recycling. Microb. Drug Resist. 1:111-114.[Medline]
33
34. Nuñez, C., S. Moreno, L. Cárdenas, G. Soberón-Chavez, and G. Espín. 2000. Inactivation of the ampDE operon increases transcription of algD and affects morphology and encystment of Azotobacter vinelandii. J. Bacteriol. 182:4829-4835.[Abstract/Free Full Text]
34
35. Oh, H., J. Stenhoff, S. Jalal, and B. Wretlind. 2003. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb. Drug Resist. 8:323-328.
35
36. Oliver, A., R. Cantón, P. Campo, F. Baquero, and J. Blázquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253.[Abstract/Free Full Text]
36
37. Quénée, L., D. Lamotte, and B. Polack. 2005. Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa. BioTechniques 38:63-67.[Medline]
37
38. Simon, R., U. Priefer, and A. Puhler. 1983. A broad range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram-negative bacteria. Bio/Technology 1:784-791.[CrossRef]
38
39. Smith, A. W., and B. H. Iglewski. 1989. Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res. 17:10509.[Free Full Text]
39
40. Stapleton, P., K. Shannon, and I. Phillips. 1995. DNA sequence differences of ampD mutants of Citrobacter freundii. Antimicrob. Agents Chemother. 39:2494-2498.[Abstract]
40
41. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, and M. V. Olson. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.[CrossRef][Medline]
41
42. Vincent, J. L. 2003. Nosocomial infections in adult intensive-care units. Lancet 361:2068-2077.[CrossRef][Medline]
42
43. West, S. E., H. P. Schweizer, C. Dall, A. K. Sample, and L. J. Runyen-Janecky. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86.[CrossRef][Medline]

---

Antimicrobial Agents and Chemotherapy, May 2006, p. 1780-1787, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1780-1787.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Viedma, E., Juan, C., Acosta, J., Zamorano, L., Otero, J. R., Sanz, F., Chaves, F., Oliver, A. (2009). Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 Pseudomonas aeruginosa Isolates Producing the Extended-Spectrum {beta}-Lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53: 4930-4933 [Abstract] [Full Text]  
• Lister, P. D., Wolter, D. J., Hanson, N. D. (2009). Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin. Microbiol. Rev. 22: 582-610 [Abstract] [Full Text]  
• Strateva, T., Yordanov, D. (2009). Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 58: 1133-1148 [Abstract] [Full Text]  
• Wolter, D. J., Black, J. A., Lister, P. D., Hanson, N. D. (2009). Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. J Antimicrob Chemother 64: 294-300 [Abstract] [Full Text]  
• Pena, C., Suarez, C., Tubau, F., Juan, C., Moya, B., Dominguez, M. A., Oliver, A., Pujol, M., Ariza, J. (2009). Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 ss-Lactamase. J. Clin. Microbiol. 47: 2381-2387 [Abstract] [Full Text]  
• Yang, T.-C., Huang, Y.-W., Hu, R.-M., Huang, S.-C., Lin, Y.-T. (2009). AmpDI Is Involved in Expression of the Chromosomal L1 and L2 {beta}-Lactamases of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 53: 2902-2907 [Abstract] [Full Text]  
• Asgarali, A., Stubbs, K. A., Oliver, A., Vocadlo, D. J., Mark, B. L. (2009). Inactivation of the Glycoside Hydrolase NagZ Attenuates Antipseudomonal {beta}-Lactam Resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 2274-2282 [Abstract] [Full Text]  
• Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  
• Schmidtke, A. J., Hanson, N. D. (2008). Role of ampD Homologs in Overproduction of AmpC in Clinical Isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 3922-3927 [Abstract] [Full Text]  
• Moya, B., Juan, C., Alberti, S., Perez, J. L., Oliver, A. (2008). Benefit of Having Multiple ampD Genes for Acquiring {beta}-Lactam Resistance without Losing Fitness and Virulence in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 3694-3700 [Abstract] [Full Text]  
• Park, J. T., Uehara, T. (2008). How Bacteria Consume Their Own Exoskeletons (Turnover and Recycling of Cell Wall Peptidoglycan). Microbiol. Mol. Biol. Rev. 72: 211-227 [Abstract] [Full Text]  
• Okazaki, A., Avison, M. B. (2008). Induction of L1 and L2 {beta}-Lactamase Production in Stenotrophomonas maltophilia Is Dependent on an AmpR-Type Regulator. Antimicrob. Agents Chemother. 52: 1525-1528 [Abstract] [Full Text]  
• Gutierrez, O., Juan, C., Cercenado, E., Navarro, F., Bouza, E., Coll, P., Perez, J. L., Oliver, A. (2007). Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish Hospitals. Antimicrob. Agents Chemother. 51: 4329-4335 [Abstract] [Full Text]  
• Henrichfreise, B., Wiegand, I., Pfister, W., Wiedemann, B. (2007). Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation. Antimicrob. Agents Chemother. 51: 4062-4070 [Abstract] [Full Text]  
• Henrichfreise, B., Wiegand, I., Luhmer-Becker, I., Wiedemann, B. (2007). Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro. Antimicrob. Agents Chemother. 51: 3642-3649 [Abstract] [Full Text]  
• Wolter, D. J., Schmidtke, A. J., Hanson, N. D., Lister, P. D. (2007). Increased Expression of ampC in Pseudomonas aeruginosa Mutants Selected with Ciprofloxacin. Antimicrob. Agents Chemother. 51: 2997-3000 [Abstract] [Full Text]  
• Plasencia, V., Borrell, N., Macia, M. D., Moya, B., Perez, J. L., Oliver, A. (2007). Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. Antimicrob. Agents Chemother. 51: 2574-2581 [Abstract] [Full Text]  
• Bratu, S., Landman, D., Gupta, J., Quale, J. (2007). Role of AmpD, OprF and penicillin-binding proteins in {beta}-lactam resistance in clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 56: 809-814 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juan, C. Articles by Oliver, A. Search for Related Content PubMed PubMed Citation Articles by Juan, C. Articles by Oliver, A.